Budesonide/formoterol in a single inhaler rapidly improves lung function in adult patients with mild or moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Beclometasone diproprionate/formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 250s Year: 2002
Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Budesonide/formoterol in a single inhaler sustains lung-function improvements in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003
Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
QVA149 provides superior peak lung function in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004